Chronic inflammatory demyelinating polyneuropathy

@article{Lewis2017ChronicID,
  title={Chronic inflammatory demyelinating polyneuropathy},
  author={Richard Alan Lewis},
  journal={Current Opinion in Neurology},
  year={2017},
  volume={30},
  pages={508–512}
}
  • R. Lewis
  • Published 1 October 2017
  • Medicine
  • Current Opinion in Neurology
Purpose of review As a syndrome with typical and atypical cases, chronic inflammatory demyelinating polyneuropathy (CIDP) has been a difficult disorder to diagnose and treat. The pathophysiologic basis for CIDP has not been established, contributing to the challenges in dealing with these patients. However, as one of only a handful of treatable peripheral neuropathies, there has been a tendency to diagnose CIDP to attempt a therapeutic intervention. We are also aware that there has also been… 
Chronic inflammatory demyelinating polyradiculoneuropathy—Diagnostic pitfalls and treatment approach
TLDR
The currently available treatment options, including intravenous immunoglobulin (IVIg), corticosteroids (CCS), and plasma exchange (PE), and how to approach treatment‐refractory cases are reviewed, and the need to adopt objective outcome measures to monitor treatment response is emphasized.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as a first presentation of systemic lupus erythematosus
TLDR
The case of a 20-year-old man with diabetes mellitus (DM) and CIDP accompanied by SLE, who was diagnosed with SLE because of pancytopenia, lymphopenia, pleuropericardial effusion, proteinuria, high titer anti-nuclear antibody (ANA), and anti-dsDNA is reported.
Sporadic hereditary neuropathies misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: Pitfalls and red flags
TLDR
Nine patients diagnosed with and treated as CIDP, in whom mutations or variants of unknown significance in genes associated with hereditary neuropathies were reported, showed demyelinating signs in seven patients, mixed findings with predominant axonal damage in two patients, suggesting an inflammatory condition concomitant with the hereditary neuropathy.
Case of rare association of peripheral neuropathy with mixed connective tissue disorder
TLDR
A case of a 38-year-old man who presented with chronic additive large and small joint inflammatory polyarthritis, associated with morning stiffness, anasarca associated with frothy urine and progressive episodic, relapsing and remitting, sensorimotor lower motor neuron type quadriparesis without any bladder and bowel involvement, responds dramatically to glucocorticoid.
Inflammatory polyradiculoneuropathies: Clinical and immunological aspects, current therapies, and future perspectives
TLDR
This review summarizes the current literature of the clinical features and pathogenic mechanisms of inflammatory polyradiculoneuropathies and focuses on current therapies and new potential treatment for the future.
Dynamics of the incidence of acute and chronic inflammatory polyneuropathies in adults in the Leningrad region
TLDR
The incidence of IPNP in adults, both acute and chronic in the Leningrad region, is growing with some fluctuations, and women were more likely to get sick than men, and chronic inflammatory demyelinating polyneuropathy was noted.
Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features
TLDR
CIDP with autoantibodies should be considered as an independent disease entity, not a subtype of CIDP due to many differences, which can better characterize these disorders, help diagnose and make the most effective therapeutic decisions.
...
...

References

SHOWING 1-10 OF 25 REFERENCES
New Treatments for Chronic Inflammatory Demyelinating Polyneuropathy
TLDR
A number of novel therapies that have been used in similar autoimmune disorders and target immunopathogenic pathways common to cidP are reviewed and their applicability tocidP is reviewed.
Chronic Inflammatory Demyelinating Polyneuropathy
TLDR
The importance of clinical patterns that define treatment responsiveness and the most appropriate therapies in order to improve prognosis are emphasized, and the distinctive clinical, laboratory, and electro-diagnostic features that aid in diagnosis are reviewed.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies.
TLDR
A review of the clinical features, diagnosis, and current treatment strategies for chronic inflammatory demyelinating polyradiculoneuropathy is summarized.
Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy
TLDR
The pilot data suggest that MMF appears to be an effective therapy for patients with naive or refractory CIDP, and further controlled studies are warranted for their confirmation.
CIDP diagnostic pitfalls and perception of treatment benefit
TLDR
Over-reliance on subjective patient-reported perception of treatment benefit, liberal electrophysiologic interpretation of demyelination, and placing an overstated importance on mild or moderate cytoalbuminologic dissociation are common diagnostic errors.
An update on the management of chronic inflammatory demyelinating polyneuropathy
  • K. Gorson
  • Medicine
    Therapeutic advances in neurological disorders
  • 2012
TLDR
This review highlights current treatment strategies for CIDP, how best to utilize proven therapies such as intravenous immunoglobulin, oral prednisone, pulse dexamethasone, and plasma exchange, and when and how to use alternative immunosuppressive agents when first-line therapies are ineffective or poorly tolerated.
Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy
TLDR
Only three treatment regimens for CIDP have demonstrated benefit in randomized, controlled studies: corticosteroids, plasma exchange, and intravenous immunoglobulins (IVIg).
Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice
TLDR
The CDAS is considered a simple and reproducible tool to classify patients with CIDP according to disease activity and treatment status that can be applied easily in practice and potentially to select patients for clinical trials.
Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg
TLDR
This study provides Class IV evidence that autoantibodies to NF155 identify a CIDP subtype characterized by severe neuropathy, poor response to IVIg, and disabling tremor.
Antibodies to contactin‐1 in chronic inflammatory demyelinating polyneuropathy
TLDR
Examination of the reactivity of CIDP patients' sera against neuronal antigens and immunoprecipitation for antigen unraveling found no evidence of autoantibodies being involved in its pathogenesis.
...
...